Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1

2015420 citationsJournal Articlebronze Open Access

Authors

David Wyles · Johns Hopkins University

Peter Ruane · Ruane Medical

Mark Sulkowski · Johns Hopkins University

Douglas T. Dieterich · Icahn School of Medicine at Mount Sinai

Anne F. Luetkemeyer · University of California, San Francisco

Timothy R. Morgan · VA Long Beach Healthcare System

Kenneth E. Sherman

Abstract

Among previously untreated HIV-HCV coinfected patients receiving daclatasvir plus sofosbuvir for HCV infection, the rate of sustained virologic response across all genotypes was 97.0% after 12 weeks of treatment and 76.0% after 8 weeks. (Funded by Bristol-Myers Squibb; ALLY-2 ClinicalTrials.gov number, NCT02032888.).

Topics & Keywords

Hepatitis C virus research HIV/AIDS drug development and treatment Chronic Lymphocytic Leukemia Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 373, Issue 8, pp. 714-725

DOI: 10.1056/nejmoa1503153

Field-Weighted Citation Impact: 45.61